Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Medius Holdings Co., Ltd. 3154.T | 32 | Normal | Healthcare | Japan | 5 / 6 | $107M |
| Arcticzymes Technologies ASA AZT.OL | 63 | Stretched | Healthcare | Norway | 4 / 6 | $107M |
| Xikang Cloud Hospital Holdings Inc. 9686.HK | 60 | Stretched | Healthcare | China | 5 / 6 | $105M |
| BrainAurora Medical Technology Limited 6681.HK | 51 | Elevated | Healthcare | China | 5 / 6 | $104M |
| Black Diamond Therapeutics Inc BDTX | 18 | Contained | Healthcare | United States | 4 / 6 | $104M |
| LENZ Therapeutics Inc LENZ | 48 | Elevated | Healthcare | United States | 5 / 6 | $104M |
| Joint Corp JYNT | 48 | Elevated | Healthcare | United States | 5 / 6 | $103M |
| Japan Medical Dynamic Marketing, INC. 7600.T | 52 | Elevated | Healthcare | Japan | 5 / 6 | $103M |
| Tian An Medicare Limited 0383.HK | 45 | Elevated | Healthcare | Hong Kong | 5 / 6 | $103M |
| Eurofins-Cerep SA ALECR | 40 | Elevated | Healthcare | France | 4 / 6 | $102M |
| Apyx Medical Corp APYX | 60 | Stretched | Healthcare | United States | 5 / 6 | $102M |
| Cyclerion Therapeutics Inc CYCN | 59 | Elevated | Healthcare | United States | 3 / 6 | $102M |
| Episurf Medical AB (publ) EPIS-B | 45 | Elevated | Healthcare | Sweden | 4 / 6 | $102M |
| Cumberland Pharmaceuticals Inc CPIX | 49 | Elevated | Healthcare | United States | 5 / 6 | $100M |
| Cibus Global Ltd. Class A CBUS | 59 | Elevated | Healthcare | United States | 4 / 6 | $100M |
| Hoshi Iryo-Sanki Co., Ltd. 7634.T | 26 | Normal | Healthcare | Japan | 5 / 6 | $99M |
| Stereotaxis Inc STXS | 49 | Elevated | Healthcare | United States | 6 / 6 | $99M |
| Wenzhou Kangning Hospital Co., Ltd. 2120.HK | 44 | Elevated | Healthcare | China | 4 / 6 | $99M |
| Neuraxis Inc NRXS | 49 | Elevated | Healthcare | United States | 5 / 6 | $98M |
| Sedana Medical AB SEDANA | 56 | Elevated | Healthcare | Sweden | 4 / 6 | $97M |
| EuroEyes International Eye Clinic Limited 1846.HK | 25 | Normal | Healthcare | Germany | 5 / 6 | $97M |
| Dimerix Ltd DXB | 38 | Normal | Healthcare | Australia | 3 / 6 | $96M |
| Tonix Pharmaceuticals Holding Corp TNXP | 63 | Stretched | Healthcare | United States | 5 / 6 | $96M |
| Nyxoah SA NYXH | 51 | Elevated | Healthcare | Belgium | 5 / 6 | $95M |
| Immucell Corp ICCC | 25 | Normal | Healthcare | United States | 5 / 6 | $95M |
| HYUGA PRIMARY CARE Co.,Ltd. 7133.T | 27 | Normal | Healthcare | Japan | 5 / 6 | $95M |
| Pak Fah Yeow International Limited 0239.HK | 16 | Contained | Healthcare | Hong Kong | 5 / 6 | $95M |
| Insight Molecular Diagnostics Inc IMDX | 75 | Stretched | Healthcare | United States | 5 / 6 | $94M |
| Kintor Pharmaceutical Limited 9939.HK | 63 | Stretched | Healthcare | China | 5 / 6 | $94M |
| Cellectis CLLS | 49 | Elevated | Healthcare | France | 5 / 6 | $93M |
| Guerbet GBT.PA | 45 | Elevated | Healthcare | France | 6 / 6 | $93M |
| Alcidion Group Limited ALC.AX | 52 | Elevated | Healthcare | Australia | 3 / 6 | $92M |
| Stella Pharma Corporation 4888.T | 63 | Stretched | Healthcare | Japan | 5 / 6 | $92M |
| Outlook Therapeutics Inc OTLK | 77 | Stretched | Healthcare | United States | 3 / 6 | $92M |
| Medical System Network Co., Ltd. 4350.T | 42 | Elevated | Healthcare | Japan | 5 / 6 | $92M |
| Cryofocus Medtech (Shanghai) Co., Ltd. 6922.HK | 47 | Elevated | Healthcare | China | 5 / 6 | $92M |
| Kooth plc KOO | 15 | Contained | Healthcare | United Kingdom | 5 / 6 | $91M |
| Hony Media Group 0419.HK | 69 | Stretched | Healthcare | Hong Kong | 5 / 6 | $91M |
| Renascience Inc. 4889.T | 90 | Acute | Healthcare | Japan | 3 / 6 | $90M |
| Kazia Therapeutics Ltd KZIA | 64 | Stretched | Healthcare | Australia | 4 / 6 | $90M |
| Airsculpt Technologies Inc AIRS | 62 | Stretched | Healthcare | United States | 4 / 6 | $89M |
| Park Dental Partners Inc PARK | 50 | Elevated | Healthcare | United States | 3 / 6 | $89M |
| HLS Therapeutics Inc HLS | 12 | Contained | Healthcare | Canada | 4 / 6 | $89M |
| Hyphens Pharma International Limited 1J5.SI | 32 | Normal | Healthcare | Singapore | 5 / 6 | $88M |
| Milestone Pharmaceuticals Inc MIST | 75 | Stretched | Healthcare | Canada | 4 / 6 | $87M |
| Rallybio Corp RLYB | 39 | Normal | Healthcare | United States | 4 / 6 | $87M |
| Wuhan YZY Biopharma Co., Ltd. 2496.HK | 77 | Stretched | Healthcare | China | 5 / 6 | $86M |
| Lee's Pharmaceutical Holdings Limited 0950.HK | 38 | Normal | Healthcare | Hong Kong | 5 / 6 | $86M |
| Novogenia AG 7V0.DE | 64 | Stretched | Healthcare | Germany | 4 / 6 | $86M |
| Oneview Healthcare PLC ONE.AX | 61 | Stretched | Healthcare | Ireland | 4 / 6 | $86M |
| Tian An Medicare Limited SMI | 44 | Elevated | Healthcare | Hong Kong | 5 / 6 | $85M |
| Atara Biotherapeutics Inc ATRA | 25 | Normal | Healthcare | United States | 5 / 6 | $85M |
| Techno Medica Co., Ltd. 6678.T | 29 | Normal | Healthcare | Japan | 4 / 6 | $84M |
| Farminveste, S.G.P.S., S.A. MLFMV | 41 | Elevated | Healthcare | Portugal | 4 / 6 | $84M |
| Colan Totte.Co.,Ltd. 7792.T | 19 | Contained | Healthcare | Japan | 5 / 6 | $84M |
| Cue Biopharma Inc CUE | 40 | Elevated | Healthcare | United States | 4 / 6 | $84M |
| Taiko Pharmaceutical Co.,Ltd. 4574.T | 23 | Normal | Healthcare | Japan | 5 / 6 | $84M |
| QingSong Health Corporation 2661.HK | 32 | Normal | Healthcare | China | 5 / 6 | $84M |
| Ohki Healthcare Holdings Co.,Ltd. 3417.T | 44 | Elevated | Healthcare | Japan | 5 / 6 | $83M |
| Eco Animal Health Group Plc EAH | 38 | Normal | Healthcare | United Kingdom | 5 / 6 | $83M |
| ECO ANIMAL HLTH GR.LS-05 LWA | 38 | Normal | Healthcare | United Kingdom | 5 / 6 | $83M |
| 3D Medicines Inc. 1244.HK | 57 | Elevated | Healthcare | China | 5 / 6 | $83M |
| Guangdong Kanghua Healthcare Group Co., Ltd. 3689.HK | 25 | Normal | Healthcare | China | 5 / 6 | $83M |
| Hyperfine Inc - Class A HYPR | 38 | Normal | Healthcare | United States | 5 / 6 | $82M |
| Inovio Pharmaceuticals Inc INO | 72 | Stretched | Healthcare | United States | 5 / 6 | $82M |
| Fusen Pharmaceutical Company Limited 1652.HK | 49 | Elevated | Healthcare | China | 5 / 6 | $81M |
| Brii Biosciences Limited 2137.HK | 74 | Stretched | Healthcare | China | 4 / 6 | $81M |
| Abionyx Pharma SA ABNX | 86 | Acute | Healthcare | France | 5 / 6 | $80M |
| Sera Prognostics Inc Class A SERA | 70 | Stretched | Healthcare | United States | 5 / 6 | $80M |
| Nightingale Health Oyj B HEALTH.HE | 57 | Elevated | Healthcare | Finland | 5 / 6 | $80M |
| Euroapi SAS EAPI | 49 | Elevated | Healthcare | France | 5 / 6 | $79M |
| Gaush Meditech Ltd 2407.HK | 44 | Elevated | Healthcare | China | 5 / 6 | $79M |
| Daiken Medical Co., Ltd. 7775.T | 30 | Normal | Healthcare | Japan | 5 / 6 | $79M |
| WOLVES HAND Co., Ltd. 194A.T | 39 | Normal | Healthcare | Japan | 4 / 6 | $78M |
| AnGes, Inc. 4563.T | 35 | Normal | Healthcare | Japan | 4 / 6 | $78M |
| Nightingale Health Oyj B HEALTH | 57 | Elevated | Healthcare | Finland | 5 / 6 | $78M |
| BioPorto BIOPOR | 48 | Elevated | Healthcare | Denmark | 4 / 6 | $77M |
| CareCloud Inc CCLD | 46 | Elevated | Healthcare | United States | 4 / 6 | $76M |
| SAKURASAKU PLUS,Co.,Ltd. 7097.T | 27 | Normal | Healthcare | Japan | 4 / 6 | $76M |
| EC Healthcare 2138.HK | 40 | Elevated | Healthcare | Hong Kong | 5 / 6 | $76M |
| Nexstim Oyj NXTMH | 37 | Normal | Healthcare | Finland | 5 / 6 | $76M |
| ReproCELL Incorporated 4978.T | 84 | Acute | Healthcare | Japan | 4 / 6 | $76M |
| Basel Medical Group Ltd BMGL | 72 | Stretched | Healthcare | Singapore | 4 / 6 | $76M |
| Channel Therapeutics Corporation PTHS | 86 | Acute | Healthcare | United States | 5 / 6 | $75M |
| Pulmonx Corp LUNG | 57 | Elevated | Healthcare | United States | 6 / 6 | $75M |
| Rani Therapeutics Holdings Inc Class A RANI | 53 | Elevated | Healthcare | United States | 5 / 6 | $73M |
| Nutriband Inc NTRB | 76 | Stretched | Healthcare | United States | 5 / 6 | $73M |
| GIUNTI GPSY.MI | 34 | Normal | Healthcare | Italy | 5 / 6 | $73M |
| ReproCELL Incorporated 6RC | 84 | Acute | Healthcare | Japan | 4 / 6 | $73M |
| Concord Healthcare Group Co., Ltd. 2453.HK | 71 | Stretched | Healthcare | China | 5 / 6 | $72M |
| Lucid Diagnostics Inc LUCD | 49 | Elevated | Healthcare | United States | 5 / 6 | $72M |
| Outset Medical Inc OM | 57 | Elevated | Healthcare | United States | 6 / 6 | $71M |
| LENSAR Inc LNSR | 53 | Elevated | Healthcare | United States | 6 / 6 | $71M |
| Zhongzhi Pharmaceutical Holdings Limited 3737.HK | 38 | Normal | Healthcare | China | 5 / 6 | $70M |
| JMS Co.,Ltd. 7702.T | 43 | Elevated | Healthcare | Japan | 5 / 6 | $70M |
| ETHK Labs Inc. 1931.HK | 56 | Elevated | Healthcare | China | 5 / 6 | $69M |
| Medicinova Inc MNOV | 62 | Stretched | Healthcare | United States | 4 / 6 | $69M |
| Zhengye Biotechnology Holding Ltd ZYBT | 90 | Acute | Healthcare | China | 4 / 6 | $69M |
| ElectroCore Inc ECOR | 50 | Elevated | Healthcare | United States | 5 / 6 | $69M |
| China NT Pharma Group Company Limited 1011.HK | 72 | Stretched | Healthcare | Hong Kong | 4 / 6 | $69M |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.